Parkinson's Disease/Movement Disorders News

The FDA has accepted a new drug application from Amneal Pharmaceuticals Inc. for IPX203, an oral formulation of carbidopa/levodopa extended-release capsules for treatment of Parkinson’s disease, the company announced in a press release.

Oral ENT-01 treatment was safe and associated with improvements in constipation among patients with Parkinson’s disease, a study in Annals of Internal Medicine found.

CHICAGO — A literature-based discovery machine learning algorithm suggested that antihistamines could be adjuvants to levodopa for Parkinson’s disease, a poster showed at the 2022 American Neurological Association annual meeting.

CHICAGO — Stephen Reich, MD, professor of neurology at the University of Maryland School of Medicine in Baltimore, spoke at ANA 2022 about clinical features of functional movement disorders and how to best identify them.

CHICAGO — Behavioral impulsivity in Parkinson’s disease may be linked to several factors, including connections between the limbic system and motor function, per a presenter at the American Neurological Association annual meeting.

CHICAGO – Mark Hallett, MD, chief of the motor control section at NINDS, discussed the pathology and etiology of functional neurological movement disorders at ANA 2022.

CHICAGO – Ray Dorsey, MD, MBA, neurology professor at the University of Rochester, discusses a presentation he gave on environmental risk factors that may be associated with Parkinson’s disease at ANA 2022.

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.

Amydis Inc. announced that patient enrollment in underway for a phase 1/2a trial to evaluate AMDXP-2011P, a retinal imaging agent that targets protein biomarkers in patients with Parkinson’s disease and ALS.

Supernus Pharmaceuticals Inc. announced that the FDA has issued a complete response letter for its new drug application of SPN-830, requesting more information.